To date there are 28 publications with over 1800 patients reported who have received cell therapy to the knee joint, with the longest case being 11 years. Those publications which looked at efficacy of treatment all reported improvement in symptoms and/or cartilage regeneration. A full list is attached, the more recent articles tend to now focus on SVF and adipose tissue.
A recent paper presented by Dr Michalek at the 2013 International Federation for Adipose Therapeutics and Science meeting in New York revealed successful results of cell therapy for patients suffering from osteoarthritis.
Since 2011, a total of 275 patients have been recruited and followed for up to 24 months to demonstrate the therapeutic potential of freshly isolated SVF cells. At the same time, one to four joints (knees and hips) were injected with SVF cells per patient. A total number of 433 joints were treated.
Within 1-2 weeks from SVF therapy, 85% of patients were off the non-steroid analgesics and remained off these analgesics for at least 6 months. After 3 months from SVF therapy, at least 50% clinical improvement was recognized in 95%, at least 75% clinical improvement in 68%, and complete remission in 54% of patients, respectively. Within 1-2 weeks from SVF therapy 85% of patients were off the non-steroid analgesics and remain such for at least 6 months. No serious side effects, infection or cancer was associated with SVF cell therapy.
Semiquantitative clinical scale evaluation and non-steroid analgesics dependence was used as measurement of the clinical effect. Prior to testing, all patients were diagnosed with stage II-IV osteoarthritis using X-ray and ultrasound, in some cases MRI was also performed to monitor the changes before and after stem cell therapy.
This work was supported in part by the International Consortium for Cell Therapy and Immunotherapy and Czech Ministry of Education.
Clinical results and second-look arthroscopic findings after treatment with adipose-derived stem cells for knee osteoarthritis.
Almost all patients showed significant improvement in all clinical outcomes at the final follow-up examination. All clinical results significantly improved at 2-year follow-up compared to 12-month follow-up (P < 0.05). Among elderly patients aged >65 years, only five patients demonstrated worsening of Kellgren-Lawrence grade. On second-look arthroscopy, 87.5 % of elderly patients (14/16) improved or maintained cartilage status at least 2 years postoperatively. Moreover, none of the patients underwent total knee arthroplasty during this 2-year period.KNEE OSTEOARTHRITIS:
- Successful Research with SVF Cells for Therapy of 275 Patients with Osteoarthritis
- Clinical results and second-look arthroscopic findings after treatment with adipose-derived stem cells for knee osteoarthritis
- Large safety and efficacy study on SVF treatment of 91 patients for 26 months
- Macquarie Stem Cells presents data on mode of delivery of SVF to the 2012 IFATS conference
- Case study on treatment of the chondromalacia patellae by SVF
- Treatment of osteoarthritis with MSC
- Successful Treatment of chondral defects with on step surgery
- A mechanism of anti-inflammatory effects on the knee
- A safety study on knee/hip and back over 2 years for 339 patients treated with MSC
- A safety study on 41 patients over 11 years with BMSC
- Successful case study on meniscus repair using autologous SVF
- Partial medial meniscectomy and MSC repair
- Allogeneic MSC injected following partial medial meniscectomy